Before an authorization to market an immunological medicinal product or derived from human blood or human plasma can be granted, the manufacturer must demonstrate his ability to attain batch-to-batch consistency. Before an authorization to market a medicinal product derived from human blood or human plasma can be granted, the manufacturer must also demonstrate the absence of specific viral contamination, to the extent that the state of technology permits.
Recital 28, Directive (EU) 2001/83
In forcecited 1×
Opinion of Advocate General Jääskinen delivered on 7 November 2013. Octapharma France SAS v Agence nationale de sécurité du médicament et deDecision
Directive 2001/83 entered into force in December 2001. [See Article 129 of Directive 2001/83.] Even prior to its amendments by Directive 2004/27, it contained specific provisions appertaining to blood and plasma. Recital 17 states that it …
7 Nov 2013 · 62012CC0512